Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Liminatus Pharma, Inc. Warrants (LIMNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LIMNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -92% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.05 - 0.47 | Updated Date 06/26/2025 |
52 Weeks Range 0.05 - 0.47 | Updated Date 06/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Liminatus Pharma, Inc. Warrants
Company Overview
History and Background
There is no publicly available information for a company named 'Liminatus Pharma, Inc. Warrants'. Therefore, a detailed history, founding year, and milestones cannot be provided.
Core Business Areas
Leadership and Structure
Due to the lack of available information about this company, the leadership team and organizational structure cannot be described.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
Without information on the company, it's impossible to determine the specific industry and its current state.
Positioning
Without information on the company, it's impossible to determine the company's positioning within any industry.
Total Addressable Market (TAM)
Without knowing the industry Liminatus Pharma, Inc. operates in, it's impossible to determine the TAM
Upturn SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
No information is available to evaluate competitive advantages or disadvantages.
Growth Trajectory and Initiatives
Historical Growth: Since this is a hypothetical company, no historical growth data is available.
Future Projections: Since this is a hypothetical company, no future projections are available.
Recent Initiatives: Since this is a hypothetical company, no recent initiatives are available.
Summary
No information is available about Liminatus Pharma, Inc. Warrants to determine its strengths, weaknesses, or market position. The company appears to be hypothetical or not publicly known.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available internet searches.
Disclaimers:
The analysis is based on the lack of available information. The company may exist but may not have a public presence. All information is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Liminatus Pharma, Inc. Warrants
Exchange NASDAQ | Headquaters La Palma, CA, United States | ||
IPO Launch date 2025-05-01 | CEO, Treasurer & Secretary Mr. Chris Kim J.D., L.L.M. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://liminatuspharma.com |
Full time employees - | Website https://liminatuspharma.com | ||
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.